Rohdaten klinischer Prüfungen von Arzneimitteln offenlegen

This procedure concerns the public disclosure of raw data from clinical trials for medicinal products. It aims to increase transparency and allow for independent verification of study results, potentially improving drug safety and efficacy assessments. This affects pharmaceutical companies, regulatory authorities, researchers, and ultimately patients. It could lead to more informed decisions about drug approvals and treatments.